Compare TG Therapeutics Inc (TGTX) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Ultra Short Bond ETF — how do they compare? TG Therapeutics Inc trades at $54.07 (market cap $8.26B), while Vanguard Ultra Short Bond ETF trades at $49.7. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | VUSB | |
|---|---|---|
Market Cap | $8.26B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $50.03 |
52-Week Low | $26.39 | $49.60 |
Enterprise Value | $8.50B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
VUSB trades at $49.70, up 0.02% on the day, with a bullish technical signal driven by positive momentum indicators. The ETF offers a yield of approximately 4.35%, positioning it as an alternative to money-market funds. Recent dividend payments include $0.18 in April 2026 and $0.17 in May 2026, with another $0.18 scheduled for July 2026.
The outlook for VUSB is supported by potential Federal Reserve rate increases enhancing short-term bond appeal, but risks include credit and duration exposure. The ETF remains a conservative income vehicle amid a non-inverted yield curve, though its technicals show mixed signals with overbought short-term RSI.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
